Evidence map›Paper›PMID 29689094›Full record

ArticlePloS one2018

The benefit of quality control charts (QCC) for routine quantitative BCR-ABL1 monitoring in chronic myeloid leukemia.

Birgit Spiess, Nicole Naumann, Norbert Galuschek, Sébastien Rinaldetti, Ute Kossak-Roth, Irina Tarnopolscaia, Elena Felde, Alice Fabarius, Wolf-Karsten Hofmann, Susanne Saußele and 1 more

Open access · goldAbstract readEvaluation Study
In one paragraph

Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Birgit SpiessDepartment of Hematology and Oncology, University Hospital Mannheim, Heidelberg University, Mannheim, Germany.ORCID 0000-0001-9930-7069
Nicole NaumannDepartment of Hematology and Oncology, University Hospital Mannheim, Heidelberg University, Mannheim, Germany.
Norbert GaluschekDepartment of Hematology and Oncology, University Hospital Mannheim, Heidelberg University, Mannheim, Germany.
Sébastien RinaldettiDepartment of Hematology and Oncology, University Hospital Mannheim, Heidelberg University, Mannheim, Germany.
Ute Kossak-RothDepartment of Hematology and Oncology, University Hospital Mannheim, Heidelberg University, Mannheim, Germany.
Irina TarnopolscaiaDepartment of Hematology and Oncology, University Hospital Mannheim, Heidelberg University, Mannheim, Germany.
Elena FeldeDepartment of Hematology and Oncology, University Hospital Mannheim, Heidelberg University, Mannheim, Germany.
Alice FabariusDepartment of Hematology and Oncology, University Hospital Mannheim, Heidelberg University, Mannheim, Germany.
Wolf-Karsten HofmannDepartment of Hematology and Oncology, University Hospital Mannheim, Heidelberg University, Mannheim, Germany.
Susanne SaußeleDepartment of Hematology and Oncology, University Hospital Mannheim, Heidelberg University, Mannheim, Germany.
Wolfgang SeifarthDepartment of Hematology and Oncology, University Hospital Mannheim, Heidelberg University, Mannheim, Germany.
Heidelberg University · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Quantitative real-time polymerase chain reaction (qRT-PCR) is state of the art in molecular monitoring of minimal residual disease in chronic myeloid leukemia (CML). In this context, maintenance of assay fidelity and detection of technical inaccuracy are crucial. Beside multiple common negative controls for the clinical sample preparations, quality control charts (QCC) are a common validation tool to sustain high process quality by continuously recording of qRT-PCR control parameters. Here, we report on establishment and benefit of QCC in qRT-PCR-based CML diagnostics. The absolute quantification of BCR-ABL1 fusion transcripts in patient samples is based on coamplification of a serially diluted reference plasmid (pME-2). For QCC establishment the measured Ct values of each pME-2 standard dilution (4-400,000) of a test set resembling 21 sequential qRT-PCR experiments were recorded and statistically evaluated. Test set data were used for determination of warning limits (mean +/- 2-fold standard deviation) and control (intervention) limits (mean +/- 3-fold standard deviation) to allow rapid detection of defined out-of-control situations which may require intervention. We have retrospectively analyzed QCC data of 282 sequential qRT-PCR experiments (564 reactions). Data evaluation using QCCs revealed three out-of-control situations that required intervention like experiment repeats, renewal of pME-2 standards, replacement of reagents or personnel re-training. In conclusion, with minimal more effort and hands-on time QCC rank among the best tools to grant high quality and reproducibility in CML routine molecular diagnosis.

Indexed as

Diagnostic Tests, RoutineQuality ControlReal-Time Polymerase Chain ReactionCase-Control StudiesFusion Proteins, bcr-ablHumansLeukemia, Myelogenous, Chronic, BCR-ABL PositiveMedical RecordsMolecular Diagnostic TechniquesMonitoring, PhysiologicNeoplasm, ResidualPredictive Value of TestsReference StandardsReproducibility of ResultsRetrospective StudiesSoftware DesignFusion Proteins, bcr-abl

Identifiers

PMID29689094
PMCPMC5916859
OpenAlexW2800256754

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.